CYTOKINE BIOMARKERS AS PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE FOR GLATIRAMER ACETATE

摘要

PROBLEM TO BE SOLVED: To provide a method for treating multiple sclerosis or a single clinical attack consistent with multiple sclerosis.SOLUTION: A method for treatment with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier comprises the following steps: a) determining whether a human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-α concentration, IL-2 concentration and IFN-γ concentration, or a combination thereof, in the blood of the human subject; and b) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier only if the human subject is identified as a glatiramer acetate responder.SELECTED DRAWING: Figure 2A